Worawit Louthrenoo's research while affiliated with Chiang Mai University and other places
What is this page?
This page lists the scientific contributions of an author, who either does not have a ResearchGate profile, or has not yet added these contributions to their profile.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
It was automatically created by ResearchGate to create a record of this author's body of work. We create such pages to advance our goal of creating and maintaining the most comprehensive scientific repository possible. In doing so, we process publicly available (personal) data relating to the author as a member of the scientific community.
If you're a ResearchGate member, you can follow this page to keep up with this author's work.
If you are this author, and you don't want us to display this page anymore, please let us know.
Publications (211)
This study aimed to clarify the association of HLA Class I and II with dcSSc and lcSSc in Thais. HLA typing for 11 gene loci (Class I: HLA-A, B and C, and Class II [HLA-DR, DP and DQ]) was carried out using the Next Generation DNA Sequencing method (three fields) in 92 Thai patients with systemic sclerosis (55 dcSSc, 37 lcSSc) and 135 healthy contr...
Background
While glucocorticoids and immunosuppressive therapies are key treatment approaches in SLE, these therapies may contribute to damage accrual. Given the long treatment horizon of SLE, tapering of glucocorticoids and immunosuppressive therapy in stable SLE is often considered, but whether this approach impacts damage accrual is unknown.
Ob...
Background
Sarcopenia refers to decrease in skeletal mass plus low muscle strength and/or low physical performance. Sarcopenia increases risk of falls, fractures, low bone mineral density, comorbidities, and poor quality of life (QoL).
Objectives
To determine prevalence and factors associated with sarcopenia, and effect of sarcopenia on quality of...
Background
Systemic lupus erythematosus (SLE) is an autoimmune disease with a broad range of clinical manifestations and a high unmet need across patient populations. Real-world data on SLE are scattered across >50 registries worldwide with variable data collection. The Lupus Federated Data Network (LupusNet) is an interdisciplinary international i...
Background
A subset of patients with systemic lupus erythematosus (SLE) suffer serious manifestations and are relatively resistant to conventional treatments, such as combinations of glucocorticoids (GC) and immunosuppressive (IS) therapy. Clear definitions of severe refractory SLE (srSLE) are lacking, limiting its reporting in real-world data from...
Background
There has been a long-standing interest in the use of biomarkers in SLE, both to measure current disease activity and to predict disease outcomes. Erythrocyte sedimentation rate (ESR), a non-specific biomarker of inflammation, has been shown to correlate with SLE disease activity as well as predict SLE flares and organ damage in some stu...
Background
The lupus low disease activity state (LLDAS) is a treat-to-target state that has been prospectively validated as protective from organ damage, death, and loss of health-related quality of life for patients with SLE. The 2023 EULAR recommendations for the management of SLE advised a glucocorticoid (GC) dose of no more than 5mg/day [1] whe...
Background
In patients with systemic lupus erythematosus (SLE), treatment options are limited. Anti-malarials and immunosuppressive therapies are widely used even though toxicity and intolerance may limit treatment persistence, or ‘survival’. The predictors and impact of drug survival of anti-malarials and immunosuppressive therapies in SLE are unk...
Introduction
Hyperuricemia is a common complication of hematologic malignancies, and hyperuricosuria in this population has shown conflicting results. This study aimed to determine the prevalence of hyperuricemia and parameters associated with serum uric acid (SUA) and urine uric acid (UUA) in patients with lymphoma and myeloproliferative neoplasms...
Background
This study examines the association of standard-of-care systemic lupus erythematosus (SLE) medications with key outcomes such as low disease activity attainment, flares, damage accrual, and steroid-sparing, for which there is current paucity of data.
Methods
The Asia Pacific Lupus Collaboration (APLC) prospectively collects data across...
Background/Objective
To determine the prevalence of thyroid dysfunctions and thyroid autoantibodies in Thai systemic lupus erythematosus (SLE) patients, and compare them with age‐ and sex‐matched healthy controls (HCs). Associations between thyroid dysfunctions and SLE disease activity, and associated factors for thyroid dysfunctions in SLE also we...
Objective
To assess whether Lupus Low Disease Activity State (LLDAS) attainment is associated with favourable outcomes in patients with recent onset SLE.
Methods
Data from a 13-country longitudinal SLE cohort were collected prospectively between 2013 and 2020. An inception cohort was defined based on disease duration <1 year at enrolment. Patient...
Background
Studies have found that late-onset systemic lupus erythematosus (SLE) patients (age at diagnosis ≥ 50 years) had less severe disease and milder clinical course, but with higher organ damage and mortality rate than early-onset ones (age at diagnosis < 50 years). Unfortunately, direct comparison of renal manifestations and treatment outcom...
Objectives
To assess the risk of flare and damage accrual after tapering glucocorticoids (GCs) in modified serologically active clinically quiescent (mSACQ) patients with systemic lupus erythematosus (SLE).
Methods
Data from a 12-country longitudinal SLE cohort, collected prospectively between 2013 and 2020, were analysed. SLE patients with mSACQ...
Introduction
This study aimed to compare the efficacy of non‐loading versus loading low‐dose colchicine in patients with acute crystal‐associated arthritis.
Materials and Methods
All in‐patients who were admitted to Chiang Mai University Hospital with non‐arthritis disease and developed acute crystal‐associated arthritis during admission (within 4...
Background: The infliximab biosimilar CT-P13 was approved in Thailand in 2015. Methods: This open-label, multicenter, post-marketing surveillance study evaluated the safety (events of special interest [ESIs]; primary end point) and effectiveness of 46 weeks of CT-P13 treatment according to routine practice in patients with rheumatoid arthritis (RA)...
Background
Systemic lupus erythematosus (SLE) is a complex disease with heterogenous manifestations.¹ Clinical subphenotypes have been reported, but limited studies have evaluated their long-term impact.² This study utilized the data from the Asia Pacific Lupus Collaboration (APLC) cohort to evaluate subphenotypes in SLE and differences in long ter...
Background
The current commonly used definitions of flare may not be able to capture patients with a persistently active disease (PAD) course. This study sought to identity the frequency and determinants of flare and PAD in an Asia-Pacific cohort.
Methods
Data from Asia-Pacific SLE patients collected between 2013 and 2020 were included. Flare was...
Background
Lupus Low Disease Activity State (LLDAS) permits serological activity and activity in several organs including joint, muscle, and mucocutaneous activity, provided SLEDA4-2K is <=4 and other LLDAS criteria are met.
Methods
Patients in the Asia-Pacific Lupus Collaboration cohort who were recruited and followed up between 2013 and 2020 who...
Background
The development of lupus low disease activity state (LLDAS) as a treat-to-target endpoint for SLE patients has been validated. Its attainment has been associated with improved outcomes. This study aims to show whether a machine learning model can yield good results in predicting whether a patient will achieve LLDAS on their succeeding as...
This study aimed to estimate health utility and related factors among Thai patients with psoriatic arthritis (PsA). A cross-sectional study was performed on patients with PsA. A structured face-to-face interview was conducted including baseline characteristics, EQ-5D-5L (Thai Version) for health utility, the Thai version of the Health Assessment Qu...
Rheumatoid arthritis (RA) is an involving chronic systemic inflammatory disease which mainly affects the joints. Several factors including genetic, environment and infections have been acknowledged as being involved in the pathogenesis and aggravation of RA. Air pollution, particularly particulate matter is widely recognized as a cause of health pr...
Background
The lupus low disease activity state (LLDAS) treat-to-target definition sets a ceiling for acceptable disease and treatment burden in SLE. Definition of Remission in SLE (DORIS) is a more stringent state, but as it is concentric with LLDAS many patients in LLDAS also meet the DORIS remission definition. Studies in cohorts with a majority...
Background
Some studies demonstrated that withdrawal of low-dose glucocorticoids in clinically quiescent systemic lupus erythematosus (SLE) patients increased the risk of flare [1]. An international survey of 130 clinicians showed that persistent abnormal serology led to a reluctance to reduce or discontinue medications [2].
Objectives
To assess t...
Background
Systemic lupus erythematosus (SLE) has heterogeneous organ manifestations that occur in different combinations at an individual patient level. Current SLE clinical trial eligibility criteria and efficacy endpoints, based on legacy disease activity measures, have multiple weaknesses. Understanding the frequency with which different organ...
Objective
Disease activity monitoring in systemic lupus erythematosus (SLE) includes serial measurement of anti-double stranded-DNA (dsDNA) antibodies, but in patients who are persistently anti-dsDNA positive, the utility of repeated measurement is unclear. We investigated the usefulness of serial anti-dsDNA testing in predicting flare in SLE patie...
Cardiac wall rupture (CWR) is a serious and often fatal complication of myocardial infarction (MI). Despite an increase in the incidence of MI in patients with systemic lupus erythematosus (SLE), cases of CWR in these patients have been reported rarely. This study reports an SLE patient with CWR and pseudoaneurysm formation and reviews previously r...
Abstract Background Several studies have compared the clinical features and outcomes of late- and early-onset systemic lupus erythematosus (SLE) patients. However, these previous studies were uncontrolled. The current study aimed to compare late- and early-onset SLE patients while controlling for sex and year at diagnosis (± 1 year). Methods The me...
Objectives
This study aimed to assess the cost-effectiveness of biologic disease-modifying antirheumatic drugs (bDMARDs) for treating patients with psoriatic arthritis who failed conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).
Methods
A decision tree and Markov model were constructed to capture long-term costs and outcomes...
Objective
In trials of systemic lupus erythematosus (SLE), the SLE Responder Index (SRI) is the most commonly used primary efficacy end point but has limited validation against long‐term outcomes. We aimed to investigate associations of attainment of a modified version of the SRI (mSRI) with key clinical outcomes in SLE patients with up to 5 years...
Abstract
Objective: In trials of systemic lupus erythematosus (SLE), the SLE Responder Index (SRI) is the most commonly used primary efficacy end point but has limited validation against long-term outcomes. We aimed to investigate associations of attainment of a modified version of the SRI (mSRI) with key clinical outcomes in SLE patients with up t...
Background
The selection and categorisation of laboratory tests in disease activity measures used within systemic lupus erythematosus (SLE) trial endpoints lack strong evidence. We aimed to determine whether longitudinal improvements in routinely measured laboratory tests are associated with measures of clinical improvement in patients with baselin...
Background
Treat-to-target goals for patients with systemic lupus erythematosus (SLE) have been validated to protect against organ damage and to improve quality of life. We aimed to investigate the association between lupus low disease activity state (LLDAS) and remission and risk of mortality in patients with SLE. We hypothesised that LLDAS has a...
Introduction:
HLA studies in patients with systemic sclerosis (SSc) have shown variable results. This study aimed to examine the association of HLA class I and II risk alleles in Thai SSc patients, and clarify the contribution of risk HLA alleles to the pathogenesis and clinical manifestations.
Methods:
Blood samples from 92 SSc patients and 135...
Introduction/objectivesScleroderma is a rare complication in taxanes therapy. Although individual cases of taxanes-induced scleroderma have been reported, the clinical manifestation and treatment outcomes were reviewed and summarized rarely. This study reported a patient who developed diffuse scleroderma and possible scleroderma renal crisis after...
Objective
Evidence for the utility of medications in settings lacking randomized trial data can come from studies of treatment persistence. The present study was undertaken to examine patterns of medication use in systemic lupus erythematosus (SLE) using data from a large multicenter longitudinal cohort.
Methods
Prospectively collected data from t...
Reports of inflammatory rheumatic diseases (IRD) in thalassemia are limited. This study aimed to determine the prevalence and clinical characteristics of IRD in patients with thalassemia disease. Consecutive adult patients with thalassemia disease, confirmed by hemoglobin typing, attending the Hematology Clinic between June 2019 and May 2021 were i...
Adult-onset Still's disease (AOSD)-like syndrome has rarely been reported as a complication of COVID-19 vaccination. This study reports a 31-year-old female patient who presented with fever, myalgia, arthralgia, pleuropericarditis, leukocytosis, and transaminitis following ChAdOx1 vaccination, and met Yamaguchi's criteria. A PubMed literature searc...
Background
In SLE patients, episodes of high disease activity state (HDAS, SLEDAI-2K≥10) are associated with worse outcomes even if only experienced once. We investigated whether attainment of the lupus low disease activity state (LLDAS) was associated with protection against adverse outcomes in SLE patients after an episode of HDAS.
Objectives
To...
Background
Lupus low disease activity state (LLDAS) attainment has been reported to be associated with reduced damage accrual, flare, and mortality, as well as improved quality of life, in cohorts of SLE patients with established disease. Whether these associations are present in recent-onset disease is less well known.
Objectives
To evaluate the...
The Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus (PISCOS) study aimed to obtain an evidence-based and expert-based consensus standardisation of the Physician Global Assessment (PGA) scoring of disease activity in systemic lupus erythematosus (SLE). An international panel of 79 SLE experts parti...
Background
The unmet need in systemic lupus erythematosus (SLE) with the current standard of care is widely recognised, but few studies have quantified this. The recent definition of treat-to-target endpoints and other thresholds of uncontrolled disease activity provide an opportunity to formally define unmet need in SLE. In this study, we enumerat...
Objectives:
This study is aimed at determining the role of T cells by assessing the numbers of IFN-γ- and IL-2-secreting T cells following stimulation with peptides derived from DNA topoisomerase-I protein in Thai SSc patients.
Methods:
Fifty Thai SSc patients and 50 healthy controls (HC) joined this study. IFN-γ and IL-2 levels upon stimulation...
Objectives
To translate the Gout Assessment Questionnaire version 2.0 (GAQ2.0) with Gout Impact (GI) Scale (GIS) into Thai and determine its psychometric property in gout patients with acute arthritis (acute arthritis group) and during the intercritical period (chronic gout group).Methods
Translation followed the ISPOR recommendations. Cronbach’s α...
Background: Nowadays, we have standard treatment guidelines for lupus nephritis (LN), a substantial proportion of patients have LN flare. The aims here to determine the incidence of LN flare in patients who had renal complete remission (CR) after receiving induction therapy (IT) and to identify factors associated with renal flare after CR in clinic...
Objectives: This study aims to compare pregnancy outcomes between systemic lupus erythematosus (SLE) patients who attained clinical remission based on the Definition of Remission in SLE (DORIS) and those with lupus low disease activity based on Low Lupus Disease Activity State (LLDAS).
Patients and methods: Between January 1993 and June 2017, a tot...
Background
Gout is the most prevalent inflammatory arthritis in the Asia-Pacific region and worldwide. This clinical practice guideline (CPG) aims to provide recommendations based on systematically obtained evidence and values and preferences tailored to the unique needs of patients with gout and hyperuricemia in Asia, Australasia, and the Middle E...
Physical disability and severity of skin disease are important factors for evaluating healthy utility in psoriatic arthritis (PsA) patient. This study aims to estimate health utility and its related factors incorporating both rheumatologic and dermatologic factors in PsA. This cross-sectional study performed in PsA patients in Thailand. EQ-5D-5L, H...
Background
The adjusted-Global Antiphospholipid Syndrome Score (aGAPSS) has been validated and used to predict antiphospholipid antibodies (aPL) related to vascular thrombosis (VT).
Objective
To validate aGAPSS for predicted aPL-related VT and pregnancy complications (PC) in Thai systemic lupus erythematosus (SLE) patients.
Methods
A cross-sectio...
Aims
Studies on polymorphisms of the cytotoxic T lymphocytes associated antigen-4 (CTLA-4) genes in rheumatic disease patients are limited in Southeast Asia. This pilot study aimed to determine CTLA-4 polymorphisms in Thai patients with rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and systemic sclerosis (SSc), and correlate them wi...
Objective
To determine longitudinal associations between Physician Global Assessment (PGA) and patient-reported outcomes (PROs) in patients with systemic lupus erythematosus (SLE).
Methods
Patients attending a rheumatology clinic between 2013 and 2017 completed specific (SLEQOL) and generic (SF36) health-related quality of life (HRQoL) surveys and...
Background/objective:
The aim of this study was to compare disease activity and rate and severity of flares between pregnant and nonpregnant systemic lupus erythematosus (SLE) patients.
Methods:
Medical records of pregnant SLE patients seen between January 1993 and June 2017 were reviewed. Nonpregnant SLE controls were matched by age at diagnosi...
Background
The recent prospectively validated definition of the lupus low disease activity state (LLDAS) allows characterisation of patients not achieving a treatment goal, providing impetus for an analysis of unmet needs in SLE using formal definitions. Other recently described definitions of high disease burden include disease activity over time,...
![ISG criteria for the diagnosis of Behcet's disease [36].](publication/351556735/figure/tbl1/AS:1022995799748609@1620912613247/ISG-criteria-for-the-diagnosis-of-Behcets-disease-36_Q320.jpg)
![Revised Japanese criteria for the diagnosis of Behcet's disease [38].](publication/351556735/figure/tbl2/AS:1022995799740418@1620912613266/Revised-Japanese-criteria-for-the-diagnosis-of-Behcets-disease-38_Q320.jpg)
Behçet’s disease (BD) is a chronic systemic inflammatory disorder characterized by recurrent oral and genital ulcers, skin lesions, and ocular inflammations. It also can affect other organs such as blood vessels, nervous, gastrointestinal, and articular systems. The disease has a worldwide distribution, but is more prevalent in countries along the...
Aim
To update previous guidance of the Asia Pacific League of Associations for Rheumatology (APLAR) on the management of patients with rheumatic and musculoskeletal diseases (RMD) during the coronavirus disease 2019 (COVID‐19) pandemic.
Methods
Research questions were formulated focusing on diagnosis and treatment of adult patients with RMD within...
Objective: The prevalence and associations of leucopenia in SLE remain incompletely
understood. We evaluated associations of disease activity and medication use with
leucopenia (lymphopenia and neutropenia) in a multinational, prospectively followed SLE
cohort.
Methods: Data from the Asia Pacific Lupus Collaboration cohort, in which disease activit...
![Figure 1 summarizes the frequency and proportion [n (%)] of visits with...](publication/350003172/figure/fig1/AS:1093393409155108@1637696711605/summarizes-the-frequency-and-proportion-n-of-visits-with-different-grades-of_Q320.jpg)
Objective
The prevalence and associations of leucopenia in SLE remain incompletely understood. We evaluated associations of disease activity and medication use with leucopenia (lymphopenia and neutropenia) in a multinational, prospectively followed SLE cohort.
Methods
Data from the Asia Pacific Lupus Collaboration cohort, in which disease activity...
Studies on predicting factors for adverse pregnancy outcomes (APOs) in Thai patients with systemic lupus erythematosus (SLE) are limited. This retrospective observation study determined APOs and their predictors in Thai patients with SLE.
Medical records of pregnant SLE patients in a lupus cohort, seen from January 1993 to June 2017, were reviewed....
Purpose of the study: Parkinsonism in patients with systemic lupus erythematosus (SLE) is rare. This study reported a case of parkinsonism in SLE and reviewed the clinical features and outcomes of parkinsonism in SLE patients.
Methods: English language literature of parkinsonism in SLE patients was reviewed.
Results: There were 28 patients (19 adul...
Objectives:
The effect of coffee on serum uric acid (SUA) has shown conflicting results. This study was to determine the effects of caffeinated coffee (CC) and decaffeinated coffee (DC) on SUA, serum xanthine oxidase activity (sXOA) and urine uric acid clearance (UAC).
Methods:
This was a prospective randomised within-subject experimental study...
Background: Flares in pregnant patients with systemic lupus erythematosus (SLE) have shown conflicting results. This study aimed to determine the disease activity, and rate and severity of flares in pregnant SLE patients compared with the non-pregnant SLE controls.
Methods: The medical records of pregnant patients in the SLE cohort were identified....
As COVID‐19 ravages healthcare systems worldwide, cases of infection among patients with systemic lupus erythematosus (SLE) are increasingly reported. While there had been 2 reports on incident hospitalized cases from the US and France,1, 2 there have been no reports of SLE patients with COVID‐19 infection from the Asia Pacific region.
The Asia Pa...
Objective:
To investigate the factors associated with discordance between patient and physician on the presence of a gout flare.
Methods:
Patients' self-reports of current gout flares were assessed with the question, 'Are you having a gout flare today?' which was then compared with a concurrent, blinded, physician's assessment. Based on agreemen...
Background
In the absence of evidence-based treatment guidelines, medication use in SLE is highly variable. Low rates of remission and lupus low disease activity state (LLDAS) suggest that suboptimal responses to standard medications, which include glucocorticoids (GC), anti-malarial (AM) drugs and immunosuppressive (IS) agents, are common. Underst...
Background:
Studies have shown that a low serum uric acid (SUA) level associates with Parkinson's disease (PD), but many of them did not exclude patients with impaired renal function. Studies on the association between serum bilirubin level and PD also are limited. This study determined the association between SUA level, SUA/serum creatinine (SCr)...
Aims:
To investigate susceptible human leukocyte antigen (HLA) alleles and their associations with clinical features in Thai patients with Behçet's disease (BD).
Method:
Eighteen HLA-A and 36 HLA-B alleles were determined in 42 Thai BD patients and 99 healthy controls (HCs) by reverse line blot assay, and reconfirmed by MICRO SSP assay.
Results...
Background:
The utility of generic health-related quality of life (HRQoL) questionnaires in patients with systemic lupus erythematosus (SLE) is uncertain. We compared the performance of generic (SF36) and specific (SLEQOL) HRQoL surveys by examining their associations with the Global Rating of Change (GRC) and SLE clinical indicators.
Methods:
T...
Objective
To examine longitudinal associations of active lupus nephritis with organ damage accrual in patients with systemic lupus erythematosus (SLE).
Methods
This study was performed using data from a large multinational prospective cohort. Active lupus nephritis at any visit was defined by the presence of urinary casts, proteinuria, haematuria...
Background
Evaluating the contribution of glucocorticoid use to organ damage in systemic lupus erythematosus is confounded by glucocorticoid use in active disease. We sought to determine the independence of the contribution of glucocorticoid use to damage accrual from associations with disease activity by analysing patients without measurable disea...
Background Validated outcome measures are needed from which to derive treatment strategies for systemic lupus
erythematosus (SLE). However, no definition of remission for SLE has been widely adopted. The Definitions of
Remission in Systemic Lupus Erythematosus (DORIS) group has proposed a framework with multiple potential
definitions of remission....
Objective
There is a lack of standardisation in the terminology used to describe gout. The aim of this project was to develop a consensus statement describing the recommended nomenclature for disease states of gout.
Methods
A content analysis of gout-related articles from rheumatology and general internal medicine journals published over a 5-year...
Background
Treat-to-target strategies have improved outcomes in single-organ diseases with simple clinical or laboratory endpoints. A lack of validated endpoints has prevented adoption of treat to target for complex multiorgan conditions, such as systemic lupus erythematosus (SLE). We report the first prospective study undertaken to specifically va...
Background
The recently validated Lupus Low Disease Activity State (LLDAS) definition has been shown to have utility as a treat to target endpoint in SLE, whereby LLDAS attainment is associated with reduction in permanent damage accrual. Robust evaluation is required to ensure this protective association is not simply reflective of milder disease p...
Background:
Observational studies have previously found associations between glucocorticoid therapy and irreversible organ damage in SLE. As glucocorticoid use and lupus disease activity are highly concordant, disease activity potentially confounds analysis of the contribution of glucocorticoid use to organ damage. This could be obviated through t...
Background
The Definitions of Remission in SLE (DORIS) group has proposed multiple definitions of remission, but these are infrequently attained and have not been prospectively evaluated in relation to protection from damage accrual. In contrast, the Lupus Low Disease Activity State (LLDAS) is more attainable, and has been shown to be associated wi...
Thalassemia patients have a high cell turnover rate due to chronic hemolysis and ineffective erythropoiesis; therefore, hyperuricemia is anticipated. This study aimed to identify the prevalence of hyperuricemia, gout and nephrolithiasis, conditions associated with serum uric acid (SUA), and urine uric acid excretion (UUA) in thalassemia patients. T...
Objective
To evaluate the efficacy and safety of diacerein in patients with rheumatoid arthritis (RA) who are methotrexate inadequate responders (MTX-IR).
Method
In this pilot, multicenter, double-blind, placebo-controlled trial, MTX-IR RA patients were randomized to either diacerein or matching placebo as add-on treatment to MTX for 24 weeks. Eff...
Background
The Definitions of Remission in SLE (DORIS) group has proposed multiple definitions of remission, but these are infrequently attained and have not previously been evaluated in relation to protection from damage accrual. In contrast, the Lupus Low Disease Activity State (LLDAS) is more attainable, and has been shown to be associated with...
Background
Adoption of treat to target approaches for Systemic Lupus Erythematosus (SLE) requires the definition of a target state validated for improved patient outcomes. The Lupus Low Disease Activity State (LLDAS) has been shown in multiple retrospective and cross-sectional studies to have face, content, construct and criterion validity and be a...
Objective
The language currently used to describe gout lacks standardization. The aim of this project was to develop a consensus statement on the labels and definitions used to describe the basic disease elements of gout.
Methods
Experts in gout (n = 130) were invited to participate in a Delphi exercise and face‐to‐face consensus meeting to reach...
Aim
To update recommendations based on current best evidence concerning the treatment of rheumatoid arthritis (RA), focusing particularly on the role of targeted therapies, to inform clinicians on new developments that will impact their current practice.
Materials and methods
A search of relevant literature from 2014 to 2016 concerning targeted th...
Aim
The aim of this manuscript is to describe the development of the Asia Pacific Lupus Collaboration (APLC) cohort.
Method
The APLC cohort is an ongoing, prospective longitudinal cohort. Adult patients who meet either the American College of Rheumatology (ACR) Modified Classification Criteria for systemic lupus erythematosus (SLE), or the Systemi...
Background
Lupus nephritis (LN) is a common feature of systemic lupus erythematosus (SLE). While LN is considered a contributor to irreversible organ damage in SLE, the magnitude of impact of active renal disease relative to other contributors to damage accrual is unknown.
Objectives
To determine the time-dependent association of active lupus neph...
Background
Patients with systemic lupus erythematosus (SLE) are commonly assessed using the classification criteria developed by the American College of Rheumatology (ACR), or more recently by the Systemic Lupus International Collaborating Clinics (SLICC). Although SLE is highly prevalent and severe in Asians, no comparison of patients meeting thes...
Objective:
This study aimed to evaluate the long-term effectiveness and safety of the first anti-tumor necrosis factor α therapy (TNFi) and to identify the associated factors of drug discontinuation in patients with spondyloarthritis.
Methods:
This was a retrospective cohort study. Patients with spondyloarthritis who were prescribed the first TN...
Posterior reversible encephalopathy syndrome (PRES) in patients with systemic lupus erythematosus (SLE) has been recognized increasingly. This study aimed to determine the prevalence, clinical features, brain imaging findings, outcomes, and associated factors of PRES in Thai SLE patients. SLE patients with PRES were identified from the lupus cohort...
Objective:
To evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of CNTO6785, a fully human monoclonal antibody that binds to human interleukin 17A, in patients with active rheumatoid arthritis (RA) with inadequate response to methotrexate (MTX) therapy.
Methods:
This randomized, double-blind, placebo-controlled, dose-ranging st...
Objective:
To perform external validation of provisional gout flare (attack) definitions in patients with gout.
Methods:
We enrolled 509 participants with gout from 17 international sites in a cross-sectional study performed during routine clinical care and collected data to classify participants as experiencing a gout flare or not according to...
Objective:
To study the response of lupus nephritis (LN) patients with persistent proteinuria (≥ 1 g/day after ≥ 6 months corticosteroid and single immunosuppressant treatment, or ≥ 3 g/day after ≥ 3 months of corticosteroid and single immunosuppressant treatment) to corticosteroid combined with two immunosuppressants, and to evaluate associated f...
Aim:
In June 2015, the Thai Rheumatism Association (TRA) approved an update of its recommendation for the use of biologic disease-modifying anti-rheumatic drugs (bDMARDs) and targeted synthetic (tsDMARD) in the treatment of rheumatoid arthritis (RA) to cover those currently available in Thailand (etanercept, infliximab, golimumab, rituximab, tocil...
Background
Treatment recommendations for patients with spondyloarthritis (SpA) who inadequately respond to non-steroidal anti-inflammatory drugs (NSAIDs) and/or traditional disease-modifying antirheumatic drugs (DMARDs) are anti-tumour necrosis factor-alpha therapy (TNFi). There has been no data on the long-term efficacy and safety of TNFi in Thai...
To evaluate the sensitivity and specificity of the 2015 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) gout classification criteria in Thai patients presenting with acute arthritis in a real-life setting. Data were analyzed on consecutive patients presenting with arthritis of less than 2?weeks duration. Sensitivity...
Citations
... In this issue of The Journal of Rheumatology, Golder et al show the different protective effects of LLDAS in patients with SLE with newly diagnosed vs those with established disease. 4 Current approaches for the management of SLE suggest that patients should achieve remission as promptly as possible; if that is not achieved, LLDAS should be the alternative outcome. 5,6 Unfortunately, remission has been achieved in less than 50% of the time in several cohorts worldwide, 7-12 with the exception of some European cohorts in which higher rates of achieving remission have been reported. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/11431281118112261-1675673048955_Q64/Yi-Hsing-Chen.jpg)
... The treatment goal is to achieve complete remission (SLEDAI = 0) or Low Lupus Disease Activity State (LLDAS) (SLE-DAI ≤ 4), as patients experiencing longer periods in these states demonstrate improved clinical outcomes [6,7]. While over 50% of SLE patients achieve remission through immunosuppressant treatments, permanent remission remains uncommon, and many patients experience flare-ups [8][9][10][11]. As such, understanding the molecular signature at various time points during the disease course is essential for developing personalized and effective treatments for different stages of SLE. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/644484765339648-1530668550076_Q64/Jiacai-Cho.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/277995433545729-1443290684758_Q64/Molla-Huq.jpg)
... Air pollutants, as an important component of these environmental factors, are defined as harmful concentrations of gaseous substances, particulate matter, and volatile substances [7]. A large number of studies from the literature have demonstrated that short-or long-term exposure to air pollutants could cause chronic inflammation, induce the disturbance of oxidative stress and DNA damage, result in serious negative effects on human health, and lead to a series of disorders that involve the respiratory, cardiovascular, and central nervous systems [8,9]. An earlier cohort study revealed that exposure to air pollutants exhibited a harmful effect on bone health, where high levels of air pollutant exposure were strongly associated with reduced BMD, and increased risk of late-life bone fractures [10]. ...
... 20 Similarly, in some patients with systemic lupus erythematosus, major declines in anti-dsDNA titers herald disease flares. 23 Whether these observations reflect antibody deposition into specific organs is not clear. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/304214029340673-1449541684523_Q64/Rachel-Koelmeyer.jpg)
... Cardiac surgeries are sometimes indicated when patients have severe clinical manifestations. Since cardiac surgery is not performed routinely, few studies on the risk factors for poor outcomes after cardiac surgery in SLE patients have been done, this information being restricted to case reports (6)(7)(8)(9)(10)(11). ...
... influenced by hormonal and genetic factors. 16 Interestingly, the average age of patients with SLE in Chile and Mexico was higher than in other countries and was similar to the average age of an Irish cohort of patients with severe lupus, many of whom had a well-established SLE. 14 In this line, expert opinions support the notion that the diagnosis of oral ulcers regarding early and established SLE is similar (45% vs. 46%). 17 This certainly occurs because studies do not separate the clinical aspects of oral lesions, in addition to the fact that lichenoid lesions are of no clinical significance in worsening or reactivating the disease, whereas ulcers may have such an action. ...
... To date, our national WTP of 160,000 THB (approximately $5003) has been recommended as the threshold for cost-effectiveness studies in Thailand [54]. It has also been used for several recent cost-effectiveness studies in Thailand [55][56][57]. Compared with the WTP threshold of the United States, which was $50,000-$100,000 per QALY gained, the difference in the WTP threshold might affect the conclusion of this study, which was inconsistent with other studies. However, our findings were in line with the previous studies [11,12,53] that found apixaban to be a dominant option compared with other DOACs. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/418481670508545-1476785213500_Q64/Piyameth-Dilokthornsakul.jpg)
![[object Object]](https://i1.rgstatic.net/ii/profile.image/279088083292170-1443551192683_Q64/Unchalee-Permsuwan.jpg)
... In the present investigation, we observed a strong inverse association between serum albumin levels and impending renal flare, which remained significant after adjustments. While this was beyond the scope of the present study, investigation of variations over time in biomarker levels as predictors of clinical response and flares as a complement to baseline levels would have merit, as proposed in previous research [28,29]. ...
![[object Object]](https://i1.rgstatic.net/ii/profile.image/710575474618374-1546425803195_Q64/Kathryn-Connelly.jpg)
... The broad spectrum of clinical manifestations can affect various organs, including the joints, skin, nervous system, hemopoietic system, lungs, kidneys, heart and blood vessels. In recent decades, early diagnosis, therapeutic advances and clinical follow-up have reduced the mortality rate of lupus patients, although it remains higher than the general population [123,124]. ...
... 23 These two outcomes were selected as primary endpoints, due to their robust associations with prognosis in SLE. SRI4 4 is the most common SLE trial endpoint; we generated a modified SRI4 for this study (mSRI), 24 excluding the use of BILAG. This is unlikely to impact upon the measure, as SRI response classification is almost entirely driven by SLEDAI. ...
